iCAD to Report Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025
iCAD (NASDAQ: ICAD), a global leader in AI-powered cancer detection solutions, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 19, 2025, after market close. The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss the results. Investors can access the call through toll-free (877-545-0523) or international (973-528-0016) numbers using participant code 174549, or via webcast.
iCAD (NASDAQ: ICAD), un leader globale nelle soluzioni di rilevamento del cancro alimentate dall'IA, ha programmato l'annuncio dei suoi risultati finanziari per il quarto trimestre e l'intero anno 2024 per il 19 marzo 2025, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica alle 16:30 ora orientale lo stesso giorno per discutere i risultati. Gli investitori possono accedere alla chiamata tramite numeri gratuiti (877-545-0523) o internazionali (973-528-0016) utilizzando il codice partecipante 174549, oppure tramite webcast.
iCAD (NASDAQ: ICAD), un líder global en soluciones de detección de cáncer impulsadas por IA, ha programado el anuncio de sus resultados financieros para el cuarto trimestre y el año completo 2024 para el 19 de marzo de 2025, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica a las 4:30 PM, hora del Este, el mismo día para discutir los resultados. Los inversores pueden acceder a la llamada a través de números gratuitos (877-545-0523) o internacionales (973-528-0016) utilizando el código de participante 174549, o a través de webcast.
iCAD (NASDAQ: ICAD), AI 기반 암 탐지 솔루션의 글로벌 리더,는 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 19일 시장 종료 후로 예정했습니다. 회사는 같은 날 동부 표준시 기준 오후 4시 30분에 결과를 논의하기 위한 컨퍼런스 콜을 개최합니다. 투자자는 무료 전화번호 (877-545-0523) 또는 국제 전화번호 (973-528-0016)를 통해 참가자 코드 174549를 사용하여 전화를 접속하거나 웹캐스트를 통해 접속할 수 있습니다.
iCAD (NASDAQ: ICAD), un leader mondial dans les solutions de détection du cancer alimentées par l'IA, a prévu d'annoncer ses résultats financiers pour le quatrième trimestre et l'année complète 2024 le 19 mars 2025, après la clôture du marché. L'entreprise organisera une conférence téléphonique à 16h30, heure de l'Est, le même jour pour discuter des résultats. Les investisseurs peuvent accéder à l'appel par le biais d'un numéro gratuit (877-545-0523) ou d'un numéro international (973-528-0016) en utilisant le code participant 174549, ou via un webinaire.
iCAD (NASDAQ: ICAD), ein globaler Marktführer im Bereich KI-gestützter Krebsdiagnoselösungen, hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 19. März 2025, nach Börsenschluss, angesetzt. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können über die gebührenfreie Nummer (877-545-0523) oder die internationale Nummer (973-528-0016) mit dem Teilnehmercode 174549 an dem Anruf teilnehmen oder über Webcast darauf zugreifen.
- None.
- None.
NASHUA, N.H., March 11, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, 2024, after market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, March 19, 2025.
Earnings call details are as follows:
Toll Free: 877-545-0523
International: 973-528-0016
Participant Access Code: 174549
Webcast: https://www.webcaster4.com/Webcast/Page/2879/52064
About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly
Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
CONTACTS
Media inquiries:
pr@icadmed.com
Investor Inquiries:
John Nesbett/Rosalyn Christian
IMS Investor Relations
icad@imsinvestorrelations.com
FAQ
When will iCAD (ICAD) release its Q4 and FY 2024 earnings?
How can investors join iCAD's Q4 2024 earnings call?
What time is iCAD's Q4 2024 earnings conference call?
What is the participant access code for iCAD's Q4 2024 earnings call?
